Cannabinoid Medication for Adults With OCD
Sponsor: |
New York State Psychiatric Institute |
Enrolling: |
Male and Female Patients |
IRB Number: |
7239 |
U.S. Govt. ID: |
NCT02911324 |
Contact: |
Marissa Raskin: 646-774-8062 / Marissa.Raskin@nyspi.columbia.edu |
The purpose of this pilot research study is to test the effects of a medication called nabilone (Cesamet) in adults with obsessive-compulsive disorder (OCD). Participants will receive either nabilone on its own, or nabilone in combination with a form of cognitive-behavioral therapy (CBT) called exposure and response prevention (EX/RP). Nabilone is a synthetic cannabinoid and acts on the brain's "endocannabinoid system," which has been hypothesized to play a role in OCD. Nabilone is approved by the FDA for the treatment of chemotherapy-induced nausea and vomiting. It is not FDA-approved for treating OCD.
This study is closed
Investigator
Helen Simpson, MD, PhD
Are you between the ages of 18 and 60? |
Yes |
No |
Do you have bothersome OCD symptoms? |
Yes |
No |
Are you currently taking any psychiatric medications? |
Yes |
No |